For AML with NPM1 and FLT3 ITD mutations (Figure 5), one study reported that an immune profile of the absence of CD34 and HLA-DR in non-APL AML is strongly associated with NPM1 and FLT3 ITD co-mutations compared to the CD34+/HLA-DR− non-APL AML group [80]. The gene discussed is CD34; the disease is acute myeloid leukemia.